ClinVar Miner

Submissions for variant NM_000551.3(VHL):c.482G>A (p.Arg161Gln) (rs730882035)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000161092 SCV000211827 pathogenic not provided 2015-12-30 criteria provided, single submitter clinical testing This variant is denoted VHL c.482G>A at the cDNA level and p.Arg161Gln (R161Q) at the protein level. The R161Q pathogenic missense variant in the VHL gene has been reported previously in association with von Hippel Lindau disease (Chen et al., 1995; Shah et al., 2014), and its presence is consistent with the diagnosis in this patient. Functional studies of R161Q shows this variant decreases the interactions responsible for stability of the interdomains creating an open conformation with greater rotation angle and moderately inhibits binding of VHL protein to proline-hydroxylated hypoxia-inducible Factor 1A (HIF1a) peptide (Couve et al., 2014).
Invitae RCV000456958 SCV000553385 pathogenic Erythrocytosis, familial, 2; Von Hippel-Lindau syndrome 2020-09-09 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 161 of the VHL protein (p.Arg161Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in several individuals and families affected with von Hippel-Lindau syndrome (PMID: 7728151, 24707167, 12000816, 15300849, 9829911, 21362373), including one individual where it was found to be de novo (PMID: 12000816). This variant has also been shown to segregate with disease in families (PMID: 23842656, 14767570, 20120764). In the literature, this variant is also known as c.695G>A. ClinVar contains an entry for this variant (Variation ID: 182983). Experimental studies demonstrated that this missense change disrupts the ability of VHL protein to bind and degrade HIF in vitro, which correlates with abnormal expression of HIF2-alpha regulated genes in vivo (PMID: 25371412, 21715564). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000563066 SCV000664511 pathogenic Hereditary cancer-predisposing syndrome 2017-09-22 criteria provided, single submitter clinical testing The p.R161Q pathogenic mutation (also known as c.482G>A), located in coding exon 3 of the VHL gene, results from a G to A substitution at nucleotide position 482. The arginine at codon 161 is replaced by glutamine, an amino acid with highly similar properties. This well-described mutation has been identified in kindreds with multiple von Hippel Lindau (VHL) tumors including hemangioblastoma, renal cell carcinoma, and pheochromocytoma (PCC), and has also been identified in individuals with isolated PCC (Chen F et al. Hum Mutat. 1995; 5: 66-75; Zbar et al. Hum Mutat. 1996; 8(4): 348-57; Woodward E et al. Hum Mol Genet. 1997; 6(7):1051-6; Olschwang S et al. Hum Mutat. 1998;12(6):424-30; Neumann HP et al. N. Engl. J. Med. 2002 May;346(19):1459-66; Tong A et al. Chin Med Sci J. 2009 Dec;24(4):197-201; Qi XP et al. Mol Med Rep 2013 Sep;8(3):799-805; Crona J et al. PLoS ONE 2014 Jan;9(1):e86756; Shah V et al. Clin Ophthalmol 2014 Mar;8:623-8). It has been reported as a de novo finding in two individuals and segregated with disease in several families (Olschwang S et al. Hum Mutat. 1998;12(6):424-30; Neumann HP et al. N. Engl. J. Med. 2002 May;346(19):1459-66; Qi XP et al. Mol Med Rep 2013 Sep;8(3):799-805). Functional studies have shown that p.R161Q disrupts VHL function in hypoxia signaling pathways in vitro (Couvé S et al. Cancer Res. 2014 Nov;74(22):6554-64). Of note, this alteration is also designated as p.R232Q in the published literature. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
PreventionGenetics,PreventionGenetics RCV000161092 SCV000805352 pathogenic not provided 2017-06-16 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000208848 SCV001362035 pathogenic Von Hippel-Lindau syndrome 2019-08-18 criteria provided, single submitter clinical testing Variant summary: VHL c.482G>A (p.Arg161Gln) results in a conservative amino acid change located in the von Hippel-Lindau disease tumour suppressor, alpha domain (IPR024048) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251440 control chromosomes. c.482G>A has been reported in the literature in multiple individuals affected with Von Hippel-Lindau Syndrome (example Chen_1995, Zbar_1996, Stolle_1998, Santarpia_2007, Olschwang_1998). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in disruption of binding to elongin and an unstable VHL protein that is susceptible to proteasomal degradation (Schoenfeld_2000). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000161092 SCV001500282 pathogenic not provided 2020-12-01 criteria provided, single submitter clinical testing
University Health Network Clinical Genomics Labs,University Health Network RCV000208848 SCV001950139 pathogenic Von Hippel-Lindau syndrome 2017-02-22 criteria provided, single submitter clinical testing
Genomic Diagnostic Laboratory, Division of Genomic Diagnostics,Children's Hospital of Philadelphia RCV000208848 SCV000264757 pathogenic Von Hippel-Lindau syndrome 2016-02-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.